BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36831640)

  • 1. Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
    Galland L; Roussot N; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Reda M; Albuisson J; Arnould L; Boidot R; Truntzer C; Ghiringhelli F; Ladoire S
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    Gou R; Dong H; Lin B
    Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency.
    Yuan P; Ma N; Xu B
    Med Res Rev; 2024 Jun; ():. PubMed ID: 38922930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
    McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
    BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches.
    Mangogna A; Munari G; Pepe F; Maffii E; Giampaolino P; Ricci G; Fassan M; Malapelle U; Biffi S
    J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2022 May; 6():e2200085. PubMed ID: 35613413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
    Bonnet E; Haddad V; Quesada S; Baffert KA; Lardy-Cléaud A; Treilleux I; Pissaloux D; Attignon V; Wang Q; Buisson A; Heudel PE; Bachelot T; Dufresne A; Eberst L; Toussaint P; Bonadona V; Lasset C; Viari A; Sohier E; Paindavoine S; Combaret V; Pérol D; Ray-Coquard I; Blay JY; Trédan O
    J Pers Med; 2022 Sep; 12(10):. PubMed ID: 36294734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    Shao C; Chang MS; Lam FC; Marley AR; Tang H; Song Y; Miller C; Brown M; Wan I; Han J; Adeboyeje G
    J Oncol; 2022; 2022():5830475. PubMed ID: 35909902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    Pacheco-Barcia V; Muñoz A; Castro E; Ballesteros AI; Marquina G; González-Díaz I; Colomer R; Romero-Laorden N
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740616
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Huang Y; Ren S; Ding L; Jiang Y; Luo J; Huang J; Yin X; Zhao J; Fu S; Liao J
    Precis Clin Med; 2024 Jun; 7(2):pbae009. PubMed ID: 38745917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
    Miller RE; Elyashiv O; El-Shakankery KH; Ledermann JA
    Onco Targets Ther; 2022; 15():1105-1117. PubMed ID: 36217436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
    Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Ballot E; Galland L; Mananet H; Boidot R; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
    Breast Cancer Res; 2022 Nov; 24(1):80. PubMed ID: 36401316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
    van Wijk LM; Nilas AB; Vrieling H; Vreeswijk MPG
    Expert Rev Mol Diagn; 2022 Feb; 22(2):185-199. PubMed ID: 34913794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for Homologous Recombination Deficiency in Cancer.
    Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
    J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.